Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Similar articles for PubMed (Select 24347915)

1.

Plants and phytochemicals for Huntington's disease.

Choudhary S, Kumar P, Malik J.

Pharmacogn Rev. 2013 Jul;7(14):81-91. doi: 10.4103/0973-7847.120505. Review.

2.

Huntington's disease: pathogenesis to animal models.

Kumar P, Kalonia H, Kumar A.

Pharmacol Rep. 2010 Jan-Feb;62(1):1-14. Review.

4.

Oxidative damage in Huntington's disease pathogenesis.

Browne SE, Beal MF.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2061-73. Review.

PMID:
17034350
5.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

6.

Management of Huntington's disease: role of tetrabenazine.

de Tommaso M, Serpino C, Sciruicchio V.

Ther Clin Risk Manag. 2011;7:123-9. doi: 10.2147/TCRM.S17152. Epub 2011 Mar 21.

7.

Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--memantine.

Anitha M, Nandhu MS, Anju TR, Jes P, Paulose CS.

Med Hypotheses. 2011 Jan;76(1):138-40. doi: 10.1016/j.mehy.2010.09.003. Epub 2010 Oct 12.

PMID:
20943326
8.

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.

PMID:
19909260
9.

Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.

Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM.

Cell Death Differ. 2004 Apr;11(4):424-38.

10.

Cellular therapy and induced neuronal replacement for Huntington's disease.

Benraiss A, Goldman SA.

Neurotherapeutics. 2011 Oct;8(4):577-90. doi: 10.1007/s13311-011-0075-8. Review.

11.

Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.

Naia L, Ribeiro MJ, Rego AC.

Rev Neurosci. 2011 Dec 2;23(1):13-28. doi: 10.1515/RNS.2011.060. Review.

PMID:
22150069
12.

Replicating Huntington's disease phenotype in experimental animals.

Brouillet E, Condé F, Beal MF, Hantraye P.

Prog Neurobiol. 1999 Dec;59(5):427-68. Review.

PMID:
10515664
13.

Mitochondria in Huntington's disease.

Damiano M, Galvan L, Déglon N, Brouillet E.

Biochim Biophys Acta. 2010 Jan;1802(1):52-61. doi: 10.1016/j.bbadis.2009.07.012. Epub 2009 Aug 11. Review.

14.
15.

Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.

Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, Farina M.

PLoS One. 2013 Jun 14;8(6):e67658. doi: 10.1371/journal.pone.0067658. Print 2013.

16.

Huntington's disease: recent advances in diagnosis and management.

Furtado S, Suchowersky O.

Can J Neurol Sci. 1995 Feb;22(1):5-12. Review.

PMID:
7750074
17.

Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice.

Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H.

Acta Neuropathol. 2011 Apr;121(4):487-98. doi: 10.1007/s00401-010-0788-5. Epub 2010 Dec 16.

18.

Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench.

Rosenstock TR, Duarte AI, Rego AC.

Curr Drug Targets. 2010 Oct;11(10):1218-36. Review.

PMID:
20840066
19.

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.

Stack EC, Matson WR, Ferrante RJ.

Ann N Y Acad Sci. 2008 Dec;1147:79-92. doi: 10.1196/annals.1427.008. Review.

PMID:
19076433
20.

Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.

Colle D, Hartwig JM, Soares FA, Farina M.

Brain Res Bull. 2012 Mar 10;87(4-5):397-405. doi: 10.1016/j.brainresbull.2012.01.003. Epub 2012 Jan 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk